Edgewater Networks to Provide Advanced Service Assurance and SD-WAN Services for Centile’s ISTRA UC PaaS Service in the UK
Edgewater Networks, the leader in Network Edge Orchestration, announced Centile, one of Europe’s leading providers of Unified Communications platforms for operators and integrators, will be using Edgewater Networks service assurance and SD-WAN capabilities to support on-site diagnostics and remote site failover for its ISTRA Cloud PaaS offering in the UK.
Centile’s ISTRA Cloud PaaS provides a broad range of UC applications services from hosted PBX to UCaaS with seamless mobile network SIM integration. ISTRA Cloud is a carrier neutral ‘bring your own interconnects’ offering for service providers and resellers. Centile’s PaaS is the first UK offering to leverage Edgewater Networks’ market leading service assurance and SD-WAN services in the UK market.
“By leveraging Edgewater Networks’ platform, our PaaS customers will have the ability to quickly identify issues as well as be proactive to support customer premise installations without the need to send field engineers,” said Justin Hamilton-Martin, Regional Associate Director, Centile. “Edgewater Networks will also enable us to provide the industry leading failover capability to maintain service levels for sites connected via more than one WAN connection, adding essential resilience for important customer sites.”
Edgewater Networks’ service assurance and SD-WAN solutions include the cloud-based EdgeView Service Control Center and customer premises-based EdgeMarc Intelligent Edges. Network Edge Orchestration offers a host of cutting edge functionality and network intelligence capability to benefit operators, including zero-touch provisioning, configuration, security and active service management tools. IP Endpoints are connected via the EdgeMarc Intelligent Edges, giving service providers the ability to remotely monitor, manage and troubleshoot all endpoints through the EdgeView Service Control Center.
“We are delighted to be working with Centile and their ISTRA Cloud PaaS service in the UK,” said Mike Wilkinson, VP of International & Sales Development for Edgewater Networks. “Recently the UK market for hosted services has lacked real innovation; Centile are bringing some disruptive new capabilities to the channel including FMC and Edgewater Networks’ highly advanced service assurance and SD-WAN based resilience functionality.”
About Edgewater Networks
Founded in October 2002, Edgewater Networks is a market leader in enabling IP-based voice, video and data services. Service providers and enterprises of all sizes use Edgewater Networks solutions to simplify customer premise configurations for quick and smooth installations, reduce time to market and deliver rapid return on invested capital. The company helps customers deliver intelligence at the network edge with its Network Edge Orchestration platform that includes the EdgeView Service Control Center, EdgeMarc Intelligent Edges, and the QuickConnect Interoperability Lab. To learn more, please visit www.edgewaternetworks.com or follow us on Twitter at @ewn_inc.
About Centile Telecom Applications
Centile Telecom Applications (www.centile.com)
is the leading European developer of unified communications platforms
for operators and integrators. The Centile Any3 architecture – Any
service, over Any network, on Any terminal – addresses the needs of
businesses and operators seeking to deliver advanced professional
communications services to fixed and mobile users independent of the
device they’re using or the network they’re connected to. In the
fast-moving market for fixed and mobile communications, Centile ISTRA
solutions offer customers the flexibility and agility to rapidly develop
innovative new services in response to ever-changing customer
requirements. Centile supports over 100 service providers customers in
20 countries with 1M users online to date. Centile has been awarded the
Frost & Sullivan "Cloud Communication-Value Price/ Performance
Leadership” and the 2018 Internet Telephony Product of the Year Award.
LinkedIn | Facebook | Twitter
Michael Cruz, 408-351-7268
Senior Corporate Marketing Manager
Centile Telecom Applications SAS
Karine Mérouze, +33 4 97 23 12 65
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i